---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000532"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-04-11T23:59:59+00:00"
generated_at: "2026-06-17T03:42:48.917147+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Meiji and CSL Seqirus to distribute Arcturus' COVID-19 vaccine ARCT-154 in Japan

## Summary
- Meiji Seika Pharma entered a distribution agreement with CSL Seqirus for Arcturus' COVID-19 vaccine candidate ARCT-154 in Japan.
- Phase III trial of ARCT-154 started Dec 12, 2022, targeting 780 participants; enrollment completed with 828 in Feb 2023.
- Arcturus has a Collaboration and License Agreement with CSL Seqirus since Dec 8, 2022 for global rights to self-amplifying mRNA vaccines.

## SEC filing metadata
- accession: 0001193805-23-000532
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000532/0001193805-23-000532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000532/e618488_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000532
- JSON: https://secwatch.observer/filing/0001193805-23-000532.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.